CardioComm Solutions Inc V.EKG

You could of bought biotricity for 22cents

[torpedoe11]

Last Christmas.Now 3.30 per share.Biotricity represents one of the means to profitability.There are others as you know.. Login Search Toggle navigation Newswire and EDGAR, SEDAR Filing Service and Agent CardioComm Solutions to Receive Royalty Payments from Biotricity Royalty payments will be based on a per monitored patient basis Toronto, Ontario--(Newsfile Corp. - October 22, 2018) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions confirmed today progress on a royalty licencing agreement with Redwood City, California-based Biotricty Inc. ("Biotricity"). The royalty payment phase became active following confirmation that all necessary clearance and software development pre-conditions have been achieved. Based on the extensive knowledge and experience CardioComm has in the ECG services market, Biotricity contracted with the Company in order to provide support for development of Biotricity's ECG viewer software, so that they were appropriately tooled to target the USA-based mobile cardiac telemetry services market. Leveraging the Company's GlobalCardio and GUAVA ECG viewer software technologies, the browser-based, custom software solution developed was a unique product designed to specifically meet the requirements of the Bioflux device. Royalty fees are due from the use of the ECG software Cardiocomm developed, or any derivative products, on a per patient monitored basis. At the start of the work, CardioComm received an advance on the per-patient royalty fees equating to the first 12,500 monitored patients. Reaching that level of patient penetration is anticipated to take up to 24 months from December 15, 2017 (Bioflux's FDA clearance date). At the end of the two year period CardioComm expects to see appreciable royalty payments of $150,000 annually at a minimum. The Company is seeking additional partnerships with new device manufacturers that will allow them access to the Company's trusted ECG software. Such partnerships will provide these new entrants with shorter development timeframes and quicker product acceptance by consumers, physicians and patient monitoring/telemedicine organizations. To learn more about CardioComm's products and for further updates regarding HeartCheck ECG device integrations please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com. About CardioComm Solutions CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada). FOR FURTHER INFORMATION PLEASE CONTACT: Etienne Grima, Chief Executive Officer 1-877-977-9425 x227 [e-mail] [e-mail] Forward-looking statements This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information. In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations). Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. info CardioComm Solutions, Inc. Sign up for Alerts Sign up to receive news releases by email for CardioComm Solutions, Inc. or all companies belonging to the Healthcare and Hospitals, Health, Technology industries. Recent News CardioComm Solutions Expands ISO Clearance to Include Multiple Biosign Monitoring Device Integrations in Support of Remote Patient Monitoring Markets 2021-02-09 8:19 AM ET CardioComm Solutions Provides Financial Update 2021-01-10 10:40 PM ET CardioComm Collaborates with ZANA Technologies GmbH to Integrate Mobile ECG Management and Smartphone App Technologies 2019-12-03 8:45 AM ET Hashtags Similar Stories Healthcare and Hospitals Health Technology Tell Us Your Story Vancouver 380 - 1100 Melville Street Vancouver, BC, Canada V6E 4A6 Phone: [phone] Calgary 2500 - 500 4th Ave SW Calgary, AB, Canada T2P 2V6 Phone: [phone] Toronto 601 - 15 Toronto Street Toronto, ON, Canada M5C 2E3 Phone: [phone] New York 5881 - 99 Wall Street New York, NY, USA 10005 Phone: [phone] Terms of Service Anti-Spam Policy Privacy Policy Copyright 2021 Newsfile Corp. All rights reserved. Login Search Toggle navigation Newswire and EDGAR, SEDAR Filing Service and Agent CardioComm Solutions to Receive Royalty Payments from Biotricity Royalty payments will be based on a per monitored patient basis Toronto, Ontario--(Newsfile Corp. - October 22, 2018) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions confirmed today progress on a royalty licencing agreement with Redwood City, California-based Biotricty Inc. ("Biotricity"). The royalty payment phase became active following confirmation that all necessary clearance and software development pre-conditions have been achieved. Based on the extensive knowledge and experience CardioComm has in the ECG services market, Biotricity contracted with the Company in order to provide support for development of Biotricity's ECG viewer software, so that they were appropriately tooled to target the USA-based mobile cardiac telemetry services market. Leveraging the Company's GlobalCardio and GUAVA ECG viewer software technologies, the browser-based, custom software solution developed was a unique product designed to specifically meet the requirements of the Bioflux device. Royalty fees are due from the use of the ECG software Cardiocomm developed, or any derivative products, on a per patient monitored basis. At the start of the work, CardioComm received an advance on the per-patient royalty fees equating to the first 12,500 monitored patients. Reaching that level of patient penetration is anticipated to take up to 24 months from December 15, 2017 (Bioflux's FDA clearance date). At the end of the two year period CardioComm expects to see appreciable royalty payments of $150,000 annually at a minimum. The Company is seeking additional partnerships with new device manufacturers that will allow them access to the Company's trusted ECG software. Such partnerships will provide these new entrants with shorter development timeframes and quicker product acceptance by consumers, physicians and patient monitoring/telemedicine organizations. To learn more about CardioComm's products and for further updates regarding HeartCheck ECG device integrations please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com. About CardioComm Solutions CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada). FOR FURTHER INFORMATION PLEASE CONTACT: Etienne Grima, Chief Executive Officer 1-877-977-9425 x227 [e-mail] [e-mail] Forward-looking statements This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information. In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations). Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. info CardioComm Solutions, Inc. Sign up for Alerts Sign up to receive news releases by email for CardioComm Solutions, Inc. or all companies belonging to the Healthcare and Hospitals, Health, Technology industries. Recent News CardioComm Solutions Expands ISO Clearance to Include Multiple Biosign Monitoring Device Integrations in Support of Remote Patient Monitoring Markets 2021-02-09 8:19 AM ET CardioComm Solutions Provides Financial Update 2021-01-10 10:40 PM ET CardioComm Collaborates with ZANA Technologies GmbH to Integrate Mobile ECG Management and Smartphone App Technologies 2019-12-03 8:45 AM ET Hashtags Similar Stories Healthcare and Hospitals Health Technology Tell Us Your Story Vancouver 380 - 1100 Melville Street Vancouver, BC, Canada V6E 4A6 Phone: [phone] Calgary 2500 - 500 4th Ave SW Calgary, AB, Canada T2P 2V6 Phone: [phone] Toronto 601 - 15 Toronto Street Toronto, ON, Canada M5C 2E3 Phone: [phone] New York 5881 - 99 Wall Street New York, NY, USA 10005 Phone: [phone] Terms of Service Anti-Spam Policy Privacy Policy Copyright 2021 Newsfile Corp. All rights reserved.